Phase III Non-Small Cell Lung Cancer Trial Studying Nexavar (sorafenib) Tablets In Combination With Two Chemotherapeutic Agents, Bayer And Onyx

... Bayer Pharmaceuticals Corporation (NYSE: BAY) and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced the initiation of a randomized, double-blind, placebo-controlled Phase III clinical trial studying Nexavar® (sorafenib) tablets administered in combination with the chemotherapeutic agents carboplatin and paclitaxel in patients with non-small cell lung cancer (NSCLC)... click link for more info. ...